Summit Therapeutics Inc. (SMMT) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Summit Therapeutics Inc. (SMMT): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 31/100 — a percentile rank of Summit Therapeutics Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $13.3B |
| EV / EBITDA | -14.7× |
| Return on equity | -135.9% |
| ROIC | -415.4% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is Summit Therapeutics Inc. overvalued? P/B looks fair vs its 5-year range.
Independent of the events above — derived from Summit Therapeutics Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact